ZYME
Zymeworks Inc. NASDAQ Listed Apr 28, 2017$26.60
After hrs
$23.90
+0.04%
Mkt Cap $2.0B
52w Low $10.86
83.3% of range
52w High $29.75
50d MA $25.64
200d MA $21.24
P/E (TTM)
-24.6x
EV/EBITDA
0.3x
P/B
7.5x
Debt/Equity
0.1x
ROE
-30.2%
P/FCF
-57.5x
RSI (14)
—
ATR (14)
—
Beta
1.20
50d MA
$25.64
200d MA
$21.24
Avg Volume
639.5K
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
114 East 4th Avenue · Middletown, BC V5T 1G4 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.10 | -0.59 | -490.0% | 26.60 | -1.5% | -10.2% | — | — | — | — | — |
| Mar 2, 2026 | AMC | -0.35 | -0.55 | -57.1% | 23.31 | +2.1% | +4.9% | +8.2% | +6.4% | +3.3% | +4.0% | — |
| Nov 6, 2025 | AMC | -0.30 | -0.26 | +13.3% | 17.90 | -5.0% | -8.0% | +0.8% | +9.9% | +8.2% | +3.4% | — |
| Aug 7, 2025 | AMC | -0.52 | 0.03 | +105.8% | 12.16 | +2.3% | -1.2% | +2.3% | +7.1% | +14.6% | +17.6% | — |
| May 8, 2025 | AMC | -0.45 | -0.30 | +33.3% | 11.32 | +0.5% | -0.1% | +6.2% | +2.6% | -0.6% | +1.9% | — |
| Mar 5, 2025 | AMC | 0.01 | -0.31 | -3200.0% | 13.18 | -5.6% | -8.0% | -9.0% | -15.8% | -11.2% | -6.8% | — |
| Oct 31, 2024 | AMC | -0.40 | -0.39 | +2.5% | 13.70 | -6.8% | -3.1% | +7.7% | +7.0% | +13.9% | +22.4% | — |
| Aug 1, 2024 | AMC | -0.42 | -0.49 | -17.4% | 10.11 | +4.8% | +0.9% | -1.1% | +0.4% | -2.8% | +0.9% | — |
| May 2, 2024 | AMC | -0.31 | -0.42 | -35.5% | 9.00 | -1.8% | +2.2% | +0.7% | +1.3% | +0.7% | +2.6% | — |
| Mar 6, 2024 | AMC | -0.39 | -0.20 | +48.7% | 12.23 | -6.9% | -6.5% | -6.5% | -9.6% | -11.6% | -12.1% | — |
| Nov 7, 2023 | AMC | -0.55 | -0.41 | +25.5% | 7.37 | +2.6% | -3.7% | -5.7% | -1.1% | -1.4% | +3.5% | — |
| Aug 10, 2023 | AMC | -0.51 | -0.76 | -49.0% | 7.76 | -9.8% | -7.6% | -3.5% | -4.4% | -6.3% | -5.3% | — |
| May 8, 2023 | AMC | -0.64 | -0.37 | +42.2% | 8.76 | +11.8% | +12.8% | +10.6% | +13.9% | +12.6% | +12.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $24.08 | $23.88 | -0.8% | +0.7% | +5.7% | +4.4% | -3.5% | -5.0% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $25.09 | +1.2% | -2.9% | -2.2% | +2.7% | +1.4% | -6.3% |
| Mar 3 | Stifel | Maintains | Buy → Buy | — | $23.31 | $23.80 | +2.1% | +4.9% | +8.2% | +6.4% | +3.3% | +4.0% |
| Mar 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $23.31 | $23.80 | +2.1% | +4.9% | +8.2% | +6.4% | +3.3% | +4.0% |
| Dec 12 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $24.94 | $26.28 | +5.4% | +2.2% | +4.1% | +3.6% | +2.6% | +5.9% |
| Nov 21 | B. Riley Securities | Maintains | Buy → Buy | — | $23.82 | $23.82 | +0.0% | +0.8% | +4.9% | +9.9% | +14.7% | +12.1% |
| Nov 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $22.99 | $23.01 | +0.1% | -1.7% | +3.6% | +4.5% | +8.7% | +13.9% |
| Nov 19 | Stifel | Maintains | Buy → Buy | — | $22.99 | $23.01 | +0.1% | -1.7% | +3.6% | +4.5% | +8.7% | +13.9% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.90 | $24.28 | +1.6% | -3.8% | -5.4% | -0.3% | +0.5% | +4.6% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $17.90 | $17.01 | -5.0% | -8.0% | +0.8% | +9.9% | +8.2% | +3.4% |
| Oct 16 | JP Morgan | Maintains | Overweight → Overweight | — | $18.62 | $18.94 | +1.7% | -0.4% | -1.2% | -1.6% | -3.7% | -5.1% |
| Oct 14 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $18.11 | $18.96 | +4.7% | +0.7% | +2.8% | +2.4% | +1.6% | +1.2% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $12.02 | $12.32 | +2.5% | +3.5% | +8.3% | +16.0% | +19.0% | +19.5% |
| Jul 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $12.89 | $12.96 | +0.5% | +1.2% | +1.5% | +0.5% | +5.3% | +6.0% |
| Mar 10 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $12.00 | $11.77 | -1.9% | -7.5% | -2.5% | +2.3% | +4.6% | +2.1% |
| Mar 7 | Citigroup | Maintains | Buy → Buy | — | $12.13 | $12.21 | +0.7% | -1.1% | -8.5% | -3.5% | +1.2% | +3.5% |
| Dec 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.74 | $12.91 | +1.3% | +6.6% | +11.0% | +12.1% | +11.0% | +13.8% |
| Dec 16 | JP Morgan | Upgrade | Neutral → Overweight | — | $12.58 | $13.47 | +7.1% | +9.5% | +6.3% | +1.3% | +7.9% | +12.4% |
| Nov 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.68 | $13.74 | +0.4% | +4.5% | +3.8% | +4.5% | +5.4% | +3.0% |
| Nov 7 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $15.61 | $16.37 | +4.9% | +7.4% | +6.5% | +11.0% | +11.5% | +10.2% |
| Nov 4 | Citigroup | Maintains | Buy → Buy | — | $13.28 | $13.30 | +0.2% | +11.1% | +10.4% | +17.5% | +26.3% | +25.2% |
| Nov 1 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.70 | $12.77 | -6.8% | -3.1% | +7.7% | +7.0% | +13.9% | +22.4% |
| Nov 1 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $13.70 | $12.77 | -6.8% | -3.1% | +7.7% | +7.0% | +13.9% | +22.4% |
| Oct 28 | Stifel | Maintains | Buy → Buy | — | $12.93 | $13.27 | +2.6% | +2.4% | +6.0% | +7.3% | +6.0% | +2.7% |
| Aug 2 | Stifel | Maintains | Buy → Buy | — | $10.11 | $10.60 | +4.8% | +0.9% | -1.1% | +0.4% | -2.8% | +0.9% |
| Jun 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.92 | $8.99 | +0.8% | +2.0% | +1.7% | +0.6% | +7.7% | +4.9% |
| May 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.06 | $9.02 | -0.4% | +0.7% | +0.0% | +1.9% | -2.8% | +2.0% |
| May 3 | Citigroup | Maintains | Buy → Buy | — | $9.00 | $8.84 | -1.8% | +2.2% | +0.7% | +1.3% | +0.7% | +2.6% |
| May 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.00 | $8.84 | -1.8% | +2.2% | +0.7% | +1.3% | +0.7% | +2.6% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.05 | $11.15 | +0.9% | -2.2% | -2.7% | -2.5% | -2.2% | -3.1% |
| Mar 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.44 | $11.47 | +0.3% | -3.4% | -5.5% | -6.0% | -5.9% | -5.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.49 | $7.47 | -0.3% | -0.9% | -2.9% | -1.9% | -0.9% | +2.1% |
| Jun 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.94 | $8.97 | +0.3% | -1.5% | -0.6% | -2.3% | -4.7% | -6.5% |
| Jun 2 | Citigroup | Maintains | Buy → Buy | — | $8.49 | $8.50 | +0.1% | +2.1% | +5.3% | +3.8% | +4.7% | +2.8% |
| May 18 | Citigroup | Maintains | Buy → Buy | — | $9.19 | $9.24 | +0.5% | +4.4% | +6.3% | +0.0% | +0.2% | -4.2% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $8.76 | $9.79 | +11.8% | +12.8% | +10.6% | +13.9% | +12.6% | +12.1% |
| Mar 31 | JP Morgan | Maintains | Neutral → Neutral | — | $8.76 | $8.90 | +1.6% | +3.2% | +7.0% | +7.3% | +7.4% | +7.2% |
| Mar 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.52 | $8.61 | +1.1% | +4.7% | -1.6% | -3.9% | -3.8% | -4.9% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $8.08 | $8.03 | -0.6% | -1.9% | +2.1% | +4.8% | +6.8% | +2.7% |
| Mar 8 | Guggenheim | Maintains | Buy → Buy | — | $7.96 | $8.60 | +8.0% | +0.5% | +1.5% | -0.4% | +3.6% | +6.4% |
| Jan 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.41 | $9.87 | +4.9% | +4.4% | +3.9% | +3.6% | +1.8% | +1.4% |
| Jan 20 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $9.68 | $9.85 | +1.8% | +3.3% | -2.8% | +1.4% | +1.0% | +0.7% |
| Jan 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.54 | $7.63 | +1.2% | +1.7% | +6.1% | +1.5% | +0.0% | +3.4% |
| Dec 22 | Barclays | Maintains | Equal Weight → Equal Weight | — | $8.75 | $8.75 | +0.0% | +0.5% | -8.1% | -14.4% | -14.4% | -10.7% |
| Dec 20 | Jefferies | Upgrade | Hold → Buy | — | $6.79 | $7.07 | +4.1% | +4.3% | +28.9% | +29.5% | +18.4% | +10.3% |
| Nov 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.76 | $7.84 | +1.0% | +2.4% | +0.0% | +3.6% | +1.0% | +0.9% |
| Nov 1 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.43 | $7.26 | -2.3% | +0.3% | -5.4% | -0.9% | +7.4% | +7.0% |
| Oct 24 | Stifel | Maintains | Buy → Buy | — | $6.25 | $6.15 | -1.6% | -4.0% | -8.5% | -4.0% | -1.3% | +6.4% |
| Oct 21 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $6.45 | $6.31 | -2.2% | -3.1% | -7.0% | -11.3% | -7.0% | -4.3% |
| Sep 14 | Citigroup | Maintains | Buy → Buy | — | $5.00 | $4.94 | -1.2% | -1.4% | +8.0% | +13.2% | +17.6% | +14.8% |
No insider trades available.
8-K
Unknown — 8-K Filing
ZYME's new Chief Financial Officer appointment signals potential leadership restructuring that investors should monitor for strategic direction changes and financial management quality improvements.
Apr 1
8-K
Zymeworks Inc. -- 8-K Filing
Zymeworks Inc. filed an 8-K providing updates under Items 2.02 and 7.01, though specific financial details or material events are not disclosed in this summary excerpt.
Mar 2
8-K · 1.01
! Medium
Zymeworks Inc. -- 8-K 1.01: Financing / Debt Agreement
Zymeworks secured $250 million in royalty-backed financing through Zymeworks Royalty Limited Partners, providing capital to fund operations and development while leveraging future revenue streams.
Mar 2
Data updated apr 27, 2026 11:55am
· Source: massive.com